
We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immunesystem to destroy cancers. #ImmunoOncology #Oncology
Larkspur, California
Joined March 2021
- Tweets230
- Following297
- Followers155
- Likes21
We’re presenting positive Phase 2 data at #SITC26 showing remarkable anti-tumor activity with imneskibart, with and without nivolumab, in doublet CPI-refractory melanoma. In heavily pretreated patients, median PFS was 9.1 months with nivolumab and 6.9 months without nivolumab, including a confirmed complete response lasting more than 32 months. In CPI-refractory adenocarcinoma NSCLC, imneskibart with avelumab showed a median PFS of 5.8 months, a 21% confirmed ORR and an 86% DCR. bit.ly/4BLIZ2v
@sitcancer
Yesterday at #ESMO26, we presented Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma #NSCLC, a population with very limited treatment options after multiple prior therapies. The full poster is now available on our website: bit.ly/4sAXouw
#LungCancer #Immunotherapy
We presented positive Phase 2 data at #ESMO26 showing exceptional progression-free survival for patients treated with imneskibart with avelumab for CPI-refractory adenocarcinoma #NSCLC. In heavily pre-treated patients, median PFS was 5.8 months (n=14). Enrollment in this Phase 2 cohort is complete, and these results mark an important step for our lung cancer program. Read the full results: bit.ly/4ezkDz9
#LungCancer #Immunotherapy
Imneskibart is designed to keep IL-2 away from Tregs and blood vessels while still allowing it to expand effector T cells and NK cells. In our Phase 1/2 study, we're evaluating it with low-dose, subcutaneous IL-2 and avelumab in CPI-refractory adenocarcinoma NSCLC. New Phase 2 data are coming to #ESMO26 next week.
#News: We'll present new Phase 2 data for imneskibart with avelumab in CPI-refractory adenocarcinoma #NSCLC at @myESMO in Madrid. bit.ly/4yRLMWm
#ESMO26
#News: New imneskibart data are headed to the @sitcancer annual meeting.
We’ll present results from our ongoing Phase 1/2 study in CPI-refractory adenocarcinoma NSCLC and doublet CPI-refractory cutaneous melanoma.
Read the announcement: aulosbio.com/aulos-bioscienc…
#SITC26 #Immunotherapy #CancerResearch #NSCLC #Melanoma
The obstacle in IL-2 therapy goes deeper than potency alone. It’s that IL-2 also expands the regulatory T cells that suppress the immune response.
Imneskibart binds selectively to the CD25-binding portion of IL-2, keeping it from trimeric receptors on Tregs while it continues to expand effector T cells and NK cells. At #ASCO26: patients whose CD8/Treg ratio rose most experienced longer progression-free survival.
Learn more: aulosbio.com/our-approach/pl…
For patients with metastatic #melanoma whose disease progresses on potent frontline doublet checkpoint inhibitor immunotherapy, options narrow quickly. At #ASCO26, we shared Phase 2 data for imneskibart in this setting: a 33% objective response rate and 67% disease control rate in patients who received imneskibart plus low-dose, subcutaneous aldesleukin and a checkpoint inhibitor (nivolumab).
Read more: aulosbio.com/our-approach/ab…
#CancerResearch
In an interview with @TargetedOnc, Meredith McKean, MD, MPH, of Sarah Cannon Research Institute reviews the Phase 2 imneskibart data presented at #ASCO26 in doublet checkpoint inhibitor-refractory metastatic melanoma.
Dr. McKean discusses a long-standing challenge in IL-2 therapy: harnessing its anti-tumor activity without the toxicities that have historically required inpatient management. In this study, imneskibart with low-dose, subcutaneous aldesleukin, with and without a checkpoint inhibitor (nivolumab), was administered entirely outpatient, with no treatment discontinuations due to drug-related adverse events. Watch the full conversation:
targetedonc.com/view/targeti…
#CancerResearch #Immunotherapy
At #ASCO26, CEO Aron Knickerbocker joined @BiotechTV to discuss our new Phase 2 data for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, including a 33% objective response rate (ORR) and 67% disease control rate (DCR).
Aron walks through the positive results from the cohorts evaluating imneskibart and low-dose, subcutaneous aldesleukin with and without a checkpoint inhibitor (nivolumab), and outlines the next steps in our clinical development path.
#CancerResearch #Immunotherapy
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: @AulosBioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart. #ASCO26
Full video: biotechtv.com/post/aulos-bio…
Beyond melanoma, imneskibart is advancing in non-small cell lung cancer. Two ongoing Phase 2 cohorts are evaluating imneskibart and low-dose, subcutaneous aldesleukin — with and without avelumab (anti-PD-L1 with an active Fc domain and ADCC effector function) — in patients with advanced PD-L1+ #NSCLC that progressed on prior CPI therapy. We anticipate sharing clinical data by year-end.
Learn more about our approach: bit.ly/4eyC4iE
#CancerResearch #Immunotherapy #LungCancer
Our time at #ASCO26 reaffirmed why we do this work — alongside clinicians, scientists and partners committed to better outcomes for patients with cancer. At Aulos, our focus remains steady: building on the new Phase 2 data we shared for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, and continuing to advance this selective immune-activating therapy in additional checkpoint inhibitor-refractory tumors, including non-small cell lung cancer.
Thank you to the investigators, clinical teams and patients whose participation makes this progress possible.
#CancerResearch #Immunotherapy
New Phase 2 data at #ASCO26: 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma patients treated with the imneskibart triplet regimen. Read the data: bit.ly/4dIAABT
#ASCO26 #Immunotherapy #CancerResearch #IL2
At the @ASCO Annual Meeting, Aulos is presenting Phase 1/2 data for imneskibart in doublet checkpoint inhibitor-refractory cutaneous melanoma — a setting with limited options for patients following tumor progression on anti–PD-1/anti–CTLA-4 or anti–PD-1/anti–LAG-3 combinations. We’re excited to share our findings with the oncology community.
Learn more: bit.ly/4sNEEWW
#ASCO2026 #Melanoma #ImmunoOncology #Biotech #medex
The imneskibart story extends beyond the tumor microenvironment. Selective IL-2 engagement is designed to maintain immune activation while limiting toxicities — including vascular leak syndrome and pulmonary edema — that have historically constrained this pathway.
Learn more: aulosbio.com/our-approach/
#CancerEducation #ImmunoOncology #MedEd
The #TumorMicroenvironment (TME) plays a powerful role in cancer progression and treatment response.
At Aulos, we're exploring innovative therapies to effectively modulate the TME, enhancing immune responses against tumors.
Learn more about our approach: aulosbio.com/our-approach/
#CancerEducation #ImmunoOncology
The 2025 #NobelPrize in Medicine honors the scientists who discovered immunosuppressive regulatory T cells (Tregs) — a breakthrough that reshaped immunology. Imneskibart builds on this legacy by activating Teffs & NK cells while limiting Tregs in solid tumor cancers.
#Immunotherapy #Tregs #CancerResearch
This Thanksgiving, we’re grateful for the patients, families, investigators and clinical teams who make progress in immuno-oncology possible. Your trust and commitment drive every step forward.
Thank you.
#Thanksgiving
Aulos is featured in @DDWJournal’s “One to Watch” spotlight.
CEO Aron Knickerbocker explains how imneskibart was designed to minimize the challenges of immune activation, while driving durable tumor reductions in #melanoma, #NSCLC and other tumor types.
Read more: ddw-online.com/one-to-watch-…
#CancerResearch #Immunotherapy
CEO Aron Knickerbocker spoke with BiotechTV at #SITC2025 about the latest Phase 2 imneskibart data — showing responses in #melanoma and #LungCancer, and higher Teff/Treg ratios that may correlate with longer time on treatment and overall survival for patients.
Watch here: biotechtv.com/post/aulos-bio…
#CancerResearch #Immunotherapy

















